Infliximab is a chimeric monoclonal antibody (mAb) blocking the effect of tumor necrosis factor alpha (TNF-α) which has been widely used since 1999 for treatment of a number of inflammatory rheumatic diseases including rheumatoid arthritis (RA). Here, TNF is linked to rheumatoid arthritis.